Winter CME Series: Hematologic Malignancies

The University of Illinois Cancer Center is hosting its second annual Winter CME Series. Join us for Session 1 of the three-part series. Earn up to three hours of Continuing Medical Education credits per session. The series is accredited by Global Education Group.

The target audience is medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals and other providers interested in the care of patients with cancer.

Register at the conference website.

Agenda
1 – 2 p.m.: Registration, exhibits and lunch
2 – 2:05 p.m.: Introduction
2:05 – 2:50 p.m.: Update on novel treatment strategies including bispecific T-cell engagers in non-Hodgkin lymphoma (Paul Rubinstein, University of Illinois Cancer Center)
2:50 – 3:35 p.m.: Review of the advances in cellular therapy for the treatment of non-Hodgkin lymphoma and leukemias (Carlos Galvez, University of Illinois Cancer Center)
3:35 – 4:35 p.m.: Break, exhibits, non-CME ancillary event, afternoon pick me up
4:35 – 5:20 p.m.: Updates on myeloma treatment including the use of minimal residual disease (Francesca Cottini, Ohio State University Comprehensive Cancer Center)
5:20 – 6:05 p.m.: Open forum: Latest treatments in acute lymphoblastic leukemia and acute myeloid leukemia (Noah Birch and John Quigley, University of Illinois Cancer Center)
6:05 – 7 p.m.: Exhibits

Series course chair: Matias E Sanchez, Assistant Professor of Medicine, UI Health Division Hematology and Oncology, University of Illinois Cancer Center

Session 1 chair: Carlos Galvez, Assistant Professor of Medicine, UI Health Division Hematology and Oncology, University of Illinois Cancer Center

Faculty presenters
Noah Birch, University of Illinois Cancer Center

Francesca Cottini, Ohio State University Comprehensive Cancer Center

Carlos Galvez, UI Health

John Quigley, University of Illinois Cancer Center

Paul Rubinstein, University of Illinois Cancer Center

Educational goal: This session aims to educate practitioners and update their knowledge of advances in diagnosing and managing hematologic malignancies.

Learning objectives
After participating in these activities, learners will be better able to:
• Discuss the advancements and optimal strategies for the use of bispecific T-cell engagers and other novel therapies in non-Hodgkin lymphoma
• Understand the novel advancements in chimeric antigen receptor therapy for non-Hodgkin lymphoma and leukemias
• Explain how to optimize treatment selection in multiple myeloma, including the use of minimal residual disease in the therapeutic setting
• Recommend the latest treatment approaches in acute lymphoblastic and acute myeloid leukemia